In a patient with fairly controlled type 2 diabetes on metformin 1 g daily (HbA1c indicating good control) who must receive high‑dose oral dexamethasone 8 mg twice daily for subglottic edema, how should glucose be monitored and managed?

Management of Dexamethasone-Induced Hyperglycemia in a Patient on Metformin

You must immediately initiate insulin therapy—specifically NPH insulin at 0.3 units/kg/day given in two divided doses (2/3 in the morning with dexamethasone, 1/3 in early evening)—while continuing metformin and monitoring blood glucose at least 4 times daily (fasting, pre-lunch, pre-dinner, and bedtime). 1

Why Insulin is Mandatory

High-dose dexamethasone 16 mg daily will cause significant afternoon and evening hyperglycemia that metformin alone cannot control. The guideline evidence is clear: sulfonylureas are not recommended in this scenario 1, and metformin monotherapy is insufficient for glucocorticoid-induced hyperglycemia at these doses. While metformin should be continued (unless contraindicated by acute illness), insulin becomes the cornerstone of management.

Specific Insulin Regimen

Starting dose:

• NPH insulin: 0.3 units/kg/day total
• Give 2/3 of total dose in the morning (when dexamethasone is given)
• Give 1/3 of total dose in early evening
• Example: For a 70 kg patient = 21 units total → 14 units morning, 7 units evening 1

Why NPH twice daily for dexamethasone: Dexamethasone has a longer duration of action than other steroids (36-72 hours), causing sustained hyperglycemia throughout the day and evening. NPH given twice daily provides better coverage than once-daily basal insulin for this pattern 1, 2.

Glucose Monitoring Protocol

Frequency: Check blood glucose at minimum 4 times daily:

• Fasting (before breakfast)
• Pre-lunch
• Pre-dinner
• Bedtime

Target range: 70-180 mg/dL (3.9-10 mmol/L) 1

Consider more frequent monitoring (every 2-4 hours initially) if glucose levels exceed 250 mg/dL (13.9 mmol/L) 1. The evidence shows that dexamethasone can cause blood glucose to double from baseline approximately 6 hours after administration 3, with peak levels occurring around 10 hours post-dose 4.

Dose Titration Strategy

Daily adjustments:

• Increase NPH by 10% daily until fasting glucose targets are achieved 2
• If afternoon/evening glucose remains elevated despite adequate fasting control, increase the evening NPH dose preferentially
• Expect to need significantly higher doses than traditional formulas suggest—recent evidence shows insulin requirements for dexamethasone hyperglycemia are "considerably higher than traditional dosing formulas" 2

Add correction insulin:

• Use rapid-acting insulin (e.g., lispro, aspart) for glucose >180 mg/dL
• Correction scale: 1 unit per 25-50 mg/dL above 150 mg/dL target, adjusted based on insulin sensitivity 2

Critical Pitfall: Rapid Insulin Reduction After Dexamethasone Stops

Insulin requirements decline rapidly when dexamethasone is discontinued 1. On the day after the last dexamethasone dose:

• Reduce NPH by 50% immediately
• Monitor glucose every 4-6 hours for 24-48 hours
• Further reduce or discontinue insulin as glucose normalizes
• Resume metformin monotherapy once glucose stabilizes

Failure to reduce insulin promptly risks severe hypoglycemia, as the hyperglycemic effect of dexamethasone resolves within 24-48 hours while insulin action persists.

Why Not Other Options

Metformin alone: Insufficient for high-dose glucocorticoid coverage; metformin primarily reduces hepatic glucose production but cannot overcome the massive insulin resistance induced by 16 mg daily dexamethasone 5.

Sulfonylureas: Explicitly not recommended due to unpredictable hypoglycemia risk and inadequate coverage of steroid-induced hyperglycemia patterns 1.

SGLT2 inhibitors: Associated with euglycemic DKA risk, especially in acute illness settings; not appropriate for acute glucocorticoid management 2.

Once-daily basal insulin (glargine/detemir): Less flexible for dose adjustment and provides less optimal coverage for dexamethasone's prolonged hyperglycemic effect compared to twice-daily NPH 1, 6.

Patient-Specific Considerations

With baseline HbA1c of 7%, this patient has reasonable glucose control, suggesting they will likely respond to the NPH regimen. However, higher baseline HbA1c predicts greater hyperglycemic response to dexamethasone 4, so patients with poorer baseline control (HbA1c >7.5%) have nearly 100% probability of requiring insulin intervention 3.

The evidence shows that age and HbA1c are the strongest predictors of hyperglycemia severity 4, but even well-controlled patients require insulin with high-dose dexamethasone.

Duration of Monitoring

Continue intensive glucose monitoring throughout the entire dexamethasone course and for 48 hours after discontinuation. Most patients can return to their baseline metformin regimen within 2-3 days of stopping dexamethasone, once glucose levels stabilize below 180 mg/dL consistently 1.